EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Efficacy and Safety of Anlotinib in EGFR-Positive Patients with Advanced Lung Adenocarcinoma Compared with Chemotherapy: A Retrospective Study

Cuihong Cai, Qian Shen, Jingjing Shao, Jingjing Qu, Shuangshuang Zhou, Jianya Zhou iD

Technology in Cancer Research & Treatment · 2024

DOI: 10.1177/15330338241279111 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Technology in Cancer Research & Treatment, 2024. Verfasst von Cuihong Cai und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, People's Repu…. Hauptthemen laut MEDLINE: Indoles, Quinolines, ErbB Receptors, Adenocarcinoma of Lung. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Natural Science Foundation of Zhejiang Province, Zhejiang Key Research and Development Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There are no standard third-line or beyond treatments for patients with driver mutation-positive advanced lung adenocarcinoma (LUAD). Anlotinib was approved as a third-line multitarget drug in China in 2018. Limited data are available regarding the efficacy and safety of anlotinib compared with chemotherapy. To investigate the efficacy and safety of anlotinib compared with traditional chemotherapy in patients with epidermal growth factor receptor (EGFR)-positive advanced LUAD. We conducted a retrospective study of 83 EGFR mutation-positive patients with advanced LUAD between 2011 and 2022. Progression-free survival (PFS) and overall survival (OS) were the primary endpoints, whereas the objective response rate (ORR) and disease control rate (DCR) were the secondary endpoints. Anlotinib-related adverse events (AEs) were recorded to evaluate the safety of anlotinib. 39 patients with LUAD received anlotinib and 44 patients with LUAD received chemotherapy were enrolled in the study. Patients treated with anlotinib exhibited longer PFS (11.2 vs 4.5 months, P < .01) and OS (18.8 vs 15.8 months, P < .05) than patients treated with chemotherapy. There were no significant differences in ORR (7.9% vs 20.5%, P = .129) or DCR (100% vs 93.2%, P = .120) between the two groups. Anlotinib-related AEs grading 3-4 level were observed in 2 (5.1%) patients, no anlotinib-related death was recorded. Cox regression analyses of PFS and OS showed that brain metastases and age < 30 years at diagnosis had negative effects on clinical outcomes. Anlotinib is effective and safe in patients with EGFR-positive advanced LUAD. Patients without brain metastases had better clinical outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IndolesQuinolinesErbB ReceptorsAdenocarcinoma of LungLung NeoplasmsHumansMaleFemaleMiddle AgedAgedRetrospective StudiesAdultTreatment OutcomeMutationProtein Kinase InhibitorsNeoplasm StagingAntineoplastic Combined Chemotherapy ProtocolsAntineoplastic Agents

Stichwörter der Autor:innen

adenocarcinomaanlotinibefficacynon-small cell lung cancersafety

Substanzen

anlotinibIndolesQuinolinesErbB ReceptorsEGFR protein, humanProtein Kinase InhibitorsAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, People's Republic of China.
  • Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, People's Republic of China.

ORCID-Profile: Jianya Zhou

Förderung

  • Natural Science Foundation of Zhejiang Province
  • Zhejiang Key Research and Development Program

Zitieren

APA

Cai, C., Shen, Q., Shao, J., Qu, J., Zhou, S., & Zhou, J. (2024). Efficacy and Safety of Anlotinib in EGFR-Positive Patients with Advanced Lung Adenocarcinoma Compared with Chemotherapy: A Retrospective Study. Technology in Cancer Research & Treatment. https://doi.org/10.1177/15330338241279111

Vancouver

Cai C, Shen Q, Shao J, Qu J, Zhou S, Zhou J. Efficacy and Safety of Anlotinib in EGFR-Positive Patients with Advanced Lung Adenocarcinoma Compared with Chemotherapy: A Retrospective Study. Technology in Cancer Research & Treatment. 2024. doi:10.1177/15330338241279111

BibTeX
@article{Cai2024,
  author = {Cai, Cuihong and Shen, Qian and Shao, Jingjing and Qu, Jingjing and Zhou, Shuangshuang and Zhou, Jianya},
  title = {Efficacy and Safety of Anlotinib in EGFR-Positive Patients with Advanced Lung Adenocarcinoma Compared with Chemotherapy: A Retrospective Study},
  journal = {Technology in Cancer Research & Treatment},
  year = {2024},
  doi = {10.1177/15330338241279111}
}
Kostenlos starten →